TARS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.25%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $749,577.60

Tarsus Pharmaceuticals Insider Trading History Chart

Tarsus Pharmaceuticals Share Price & Price History

^$48.09

▲ +1.62 (3.49%)

As of 03/14/2025 05:00 PM ET

Days: 30 | 90 | 365

Tarsus Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Aziz Mottiwala	Insider	Sell	4,766	$30.60	$145,839.60	54,075
3/18/2024	Bobak R. Azamian	CEO	Sell	10,415	$30.60	$318,699.00	26,456
3/18/2024	Bryan Wahl	General Counsel	Sell	4,436	$30.60	$135,741.60	40,951
3/18/2024	Seshadri Neervannan	COO	Sell	4,879	$30.60	$149,297.40	64,767
12/27/2023	Bobak R. Azamian	CEO	Sell	8,000	$20.22	$161,760.00	830,106
12/20/2023	Bobak R. Azamian	CEO	Sell	40,000	$20.27	$810,800.00	838,106
12/20/2023	Jose M Trevejo	Insider	Sell	2,252	$20.00	$45,040.00	2,251
12/15/2023	Andrew D. Goldberg	Director	Buy	1,000	$18.96	$18,960.00	3,000
11/30/2023	Bryan Wahl	General Counsel	Sell	8,356	$16.31	$136,286.36	31,966
11/30/2023	Dianne C. Whitfield	Insider	Sell	8,355	$16.31	$136,270.05	26,784
10/18/2023	Bobak R. Azamian	CEO	Sell	8,000	$13.24	$105,920.00	886,106
10/5/2023	Jose M Trevejo	Insider	Sell	1,604	$18.00	$28,872.00	4,503
9/20/2023	Bobak R. Azamian	CEO	Sell	8,000	$17.21	$137,680.00	894,106
8/23/2023	Bobak R. Azamian	CEO	Sell	8,000	$17.23	$137,840.00	902,106
8/15/2023	Elizabeth Yeu Lin	Director	Buy	9,506	$16.80	$159,700.80	15,866
7/19/2023	Aziz Mottiwala	Insider	Sell	2,400	$20.05	$48,120.00	45,806
7/19/2023	Bobak R. Azamian	CEO	Sell	103,900	$20.01	$2,079,039.00	910,106
7/12/2023	Bobak R. Azamian	CEO	Sell	9,000	$17.35	$156,150.00	1,014,006
6/21/2023	Bobak R. Azamian	CEO	Sell	8,000	$18.63	$149,040.00	1,023,006
6/14/2023	Bobak R. Azamian	CEO	Sell	9,000	$18.58	$167,220.00	1,031,006
6/8/2023	Aziz Mottiwala	Insider	Sell	100	$20.00	$2,000.00	48,086
6/8/2023	Bobak R. Azamian	CEO	Sell	3,100	$20.01	$62,031.00	1,040,006
6/6/2023	Aziz Mottiwala	Insider	Sell	2,143	$18.61	$39,881.23	50,686
5/17/2023	Bobak R. Azamian	CEO	Sell	8,000	$15.90	$127,200.00	1,043,106
5/10/2023	Bobak R. Azamian	CEO	Sell	9,000	$16.80	$151,200.00	1,051,106
5/1/2023	Bobak R. Azamian	CEO	Sell	5,841	$15.10	$88,199.10	1,060,106
4/28/2023	Bobak R. Azamian	CEO	Sell	4,278	$15.13	$64,726.14	1,065,947
4/21/2023	Bobak R. Azamian	CEO	Sell	2,311	$15.03	$34,734.33	1,070,225
4/20/2023	Leonard M Greenstein	CFO	Sell	5,000	$14.02	$70,100.00	26,785
4/19/2023	Bobak R. Azamian	CEO	Sell	8,000	$13.60	$108,800.00	1,072,536
3/22/2023	Bobak R. Azamian	CEO	Sell	709	$12.64	$8,961.76	9,334
3/22/2023	Bryan Wahl	General Counsel	Sell	357	$12.64	$4,512.48	16,773
3/22/2023	Jose M Trevejo	Insider	Sell	529	$12.64	$6,686.56	6,572
3/22/2023	Leonard M Greenstein	CFO	Sell	332	$12.64	$4,196.48	32,131
3/22/2023	Seshadri Neervannan	COO	Sell	379	$12.64	$4,790.56	55,086
3/20/2023	Bobak R. Azamian	CEO	Sell	741	$12.61	$9,344.01	10,722
3/20/2023	Bryan Wahl	General Counsel	Sell	357	$12.61	$4,501.77	17,480
3/20/2023	Jose M Trevejo	Insider	Sell	530	$12.61	$6,683.30	7,620
3/20/2023	Leonard M Greenstein	CFO	Sell	333	$12.61	$4,199.13	32,789
3/20/2023	Mark J Holdbrook	VP	Sell	198	$12.61	$2,496.78	3,191
3/20/2023	Seshadri Neervannan	COO	Sell	380	$12.61	$4,791.80	55,837
3/17/2023	Bobak R. Azamian	CEO	Sell	795	$13.28	$10,557.60	11,463
3/16/2023	Bryan Wahl	General Counsel	Sell	337	$13.43	$4,525.91	18,176
3/16/2023	Dianne C. Whitfield	Insider	Sell	313	$13.43	$4,203.59	12,872
3/16/2023	Leonard M Greenstein	CFO	Sell	5,313	$13.44	$71,406.72	33,438
3/16/2023	Mark J Holdbrook	VP	Sell	187	$13.43	$2,511.41	3,577
3/16/2023	Seshadri Neervannan	COO	Sell	357	$13.43	$4,794.51	56,577
3/15/2023	Bobak R. Azamian	CEO	Sell	8,000	$13.79	$110,320.00	1,080,536
3/8/2023	Bobak R. Azamian	CEO	Sell	4,853	$15.02	$72,892.06	1,089,253
2/8/2023	Bobak R. Azamian	CEO	Sell	9,000	$15.14	$136,260.00	1,102,106
1/23/2023	Bobak R. Azamian	CEO	Sell	4,856	$15.45	$75,025.20	1,111,106
1/20/2023	Bobak R. Azamian	CEO	Sell	240	$15.00	$3,600.00	1,116,373
1/19/2023	Leonard M Greenstein	CFO	Sell	5,000	$14.56	$72,800.00	39,289
1/18/2023	Bobak R. Azamian	CEO	Sell	8,000	$14.56	$116,480.00	1,116,613
1/11/2023	Bobak R. Azamian	CEO	Sell	3,904	$15.11	$58,989.44	1,124,613
1/9/2023	Bobak R. Azamian	CEO	Sell	729	$15.15	$11,044.35	1,129,422
1/6/2023	Bobak R. Azamian	CEO	Sell	411	$15.00	$6,165.00	1,129,740
12/21/2022	Bobak R. Azamian	CEO	Sell	8,000	$14.57	$116,560.00	1,130,151
12/16/2022	Bobak R. Azamian	CEO	Sell	535	$15.01	$8,030.35	1,138,151
12/15/2022	Leonard M Greenstein	CFO	Sell	5,000	$14.64	$73,200.00	44,289
12/14/2022	Bobak R. Azamian	CEO	Sell	6,420	$15.08	$96,813.60	1,138,686
12/2/2022	Dianne C. Whitfield	Insider	Sell	1,154	$16.90	$19,502.60	8,723
11/30/2022	Bryan Wahl	General Counsel	Sell	1,183	$16.50	$19,519.50	16,041
11/30/2022	Dianne C. Whitfield	Insider	Sell	1,182	$16.50	$19,503.00	11,042
11/15/2022	Aziz Mottiwala	Insider	Sell	6,857	$17.72	$121,506.04	49,729
10/20/2022	Leonard M Greenstein	CFO	Sell	5,000	$15.92	$79,600.00	54,289
10/19/2022	Bobak R. Azamian	CEO	Sell	8,000	$16.92	$135,360.00	1,162,106
10/12/2022	Bobak R. Azamian	CEO	Sell	9,000	$15.91	$143,190.00	1,170,106
9/21/2022	Bobak R. Azamian	CEO	Sell	8,000	$16.31	$130,480.00	1,179,106
9/15/2022	Leonard M Greenstein	CFO	Sell	5,000	$16.03	$80,150.00	59,289
9/14/2022	Bobak R. Azamian	CEO	Sell	9,000	$16.01	$144,090.00	1,187,106
9/14/2022	Elizabeth Yeu Lin	Director	Buy	18,400	$16.12	$296,608.00	12,040
8/18/2022	Leonard M Greenstein	CFO	Sell	5,000	$16.30	$81,500.00	64,289
8/17/2022	Bobak R. Azamian	CEO	Sell	8,000	$16.59	$132,720.00	1,196,106
5/5/2022	D. Michael Ackermann	Director	Buy	100,000	$13.50	$1,350,000.00	100,000
5/4/2022	Vivo Capital Ix, Llc	Major Shareholder	Sell	19,738	$12.67	$250,080.46	2,474,375
5/2/2022	Vivo Capital Ix, Llc	Major Shareholder	Sell	41,800	$15.19	$634,942.00	2,945,531

See Full Table

SEC Filings (Institutional Ownership Changes) for Tarsus Pharmaceuticals (NASDAQ:TARS)

90.01% of Tarsus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Tarsus Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/21/2025	TFG Asset Management GP Ltd	200,000	$11.07M	2.4%	-67.4%	0.523%
2/19/2025	Toronto Dominion Bank	1,909,228	$105.71M	0.2%	N/A	4.994%
2/19/2025	GF Fund Management CO. LTD.	803	$44K	0.0%	N/A	0.002%
2/18/2025	Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.	59,204	$3.28M	0.4%	N/A	0.155%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	69,826	$3.87M	0.0%	+18.7%	0.183%
2/17/2025	Woodline Partners LP	108,986	$6.04M	0.0%	+52.3%	0.285%
2/17/2025	Squarepoint Ops LLC	6,004	$0.33M	0.0%	-89.5%	0.016%
2/17/2025	Two Sigma Advisers LP	53,500	$2.96M	0.0%	-79.1%	0.140%
2/17/2025	Two Sigma Investments LP	91,171	$5.05M	0.0%	-69.2%	0.238%
2/17/2025	TFG Asset Management GP Ltd	200,000	$11.07M	2.7%	-67.4%	0.523%
2/17/2025	Toronto Dominion Bank	1,909,228	$105.71M	0.2%	N/A	4.994%
2/17/2025	Sherbrooke Park Advisers LLC	6,571	$0.36M	0.1%	+7.2%	0.017%
2/17/2025	RTW Investments LP	3,236,549	$179.21M	2.7%	-5.2%	8.466%
2/17/2025	Rafferty Asset Management LLC	6,804	$0.38M	0.0%	-11.1%	0.018%
2/17/2025	ProShare Advisors LLC	12,170	$0.67M	0.0%	+32.3%	0.032%
2/17/2025	Paradigm Biocapital Advisors LP	2,531,896	$140.19M	4.9%	+3.7%	6.623%
2/17/2025	Nuveen Asset Management LLC	125,539	$6.95M	0.0%	-10.8%	0.328%
2/17/2025	Numerai GP LLC	18,668	$1.03M	0.3%	N/A	0.049%
2/17/2025	OMERS ADMINISTRATION Corp	7,400	$0.41M	0.0%	N/A	0.019%
2/17/2025	Millennium Management LLC	644,010	$35.66M	0.0%	+189.4%	1.685%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	20,926	$1.16M	0.0%	+3.6%	0.055%
2/17/2025	Integral Health Asset Management LLC	350,000	$19.38M	1.7%	-6.7%	0.916%
2/17/2025	Janus Henderson Group PLC	12,482	$0.69M	0.0%	+47.2%	0.033%
2/17/2025	Ensign Peak Advisors Inc	570,056	$31.56M	0.1%	-2.9%	1.491%
2/17/2025	Deutsche Bank AG	153,441	$8.50M	0.0%	+93.8%	0.401%
2/17/2025	D. E. Shaw & Co. Inc.	365,544	$20.24M	0.0%	+100.7%	0.956%
2/17/2025	Corton Capital Inc.	4,714	$0.26M	0.1%	N/A	0.012%
2/17/2025	Cutter Capital Management LP	112,500	$6.23M	2.6%	N/A	0.294%
2/17/2025	Caxton Associates LP	16,588	$0.92M	0.0%	N/A	0.043%
2/17/2025	Baird Financial Group Inc.	142,419	$7.89M	0.0%	-2.7%	0.373%
2/17/2025	Bayesian Capital Management LP	4,114	$0.23M	0.0%	N/A	0.011%
2/17/2025	Bank of America Corp DE	337,856	$18.71M	0.0%	+44.7%	0.884%
2/17/2025	BNP Paribas Financial Markets	4,848	$0.27M	0.0%	N/A	0.013%
2/17/2025	Ameriprise Financial Inc.	47,685	$2.64M	0.0%	+21.2%	0.125%
2/17/2025	Allostery Investments LP	13,600	$0.75M	0.8%	N/A	0.036%
2/17/2025	Ally Bridge Group NY LLC	173,144	$9.59M	8.0%	-46.2%	0.453%
2/14/2025	Freestone Grove Partners LP	7,921	$0.44M	0.0%	N/A	0.021%
2/14/2025	Voleon Capital Management LP	5,266	$0.29M	0.0%	N/A	0.014%
2/14/2025	Schonfeld Strategic Advisors LLC	9,800	$0.54M	0.0%	-94.8%	0.026%
2/14/2025	Northern Trust Corp	357,616	$19.80M	0.0%	+12.6%	0.935%
2/14/2025	The Manufacturers Life Insurance Company	46,777	$2.59M	0.0%	+42.1%	0.122%
2/14/2025	Tudor Investment Corp ET AL	13,880	$0.77M	0.0%	N/A	0.036%
2/14/2025	Quarry LP	3,000	$0.17M	0.0%	N/A	0.008%
2/14/2025	Artia Global Partners LP	20,811	$1.15M	0.4%	N/A	0.054%
2/14/2025	Boothbay Fund Management LLC	156,403	$8.66M	0.2%	-43.2%	0.409%
2/14/2025	Virtus ETF Advisers LLC	6,845	$0.38M	0.2%	-31.1%	0.018%
2/14/2025	Gilder Gagnon Howe & Co. LLC	404,237	$22.38M	0.2%	+5,636.3%	1.057%
2/14/2025	Lord Abbett & CO. LLC	1,279,987	$70.87M	0.2%	+115.2%	3.348%
2/14/2025	Voya Investment Management LLC	30,033	$1.66M	0.0%	+149.6%	0.079%
2/14/2025	Price T Rowe Associates Inc. MD	460,773	$25.51M	0.0%	+92.5%	1.205%
2/14/2025	Silverarc Capital Management LLC	65,955	$3.65M	0.8%	+64.9%	0.173%
2/14/2025	Diadema Partners LP	60,000	$3.32M	1.4%	N/A	0.157%
2/14/2025	Hsbc Holdings PLC	4,934	$0.27M	0.0%	-23.6%	0.013%
2/14/2025	Rock Springs Capital Management LP	110,889	$6.14M	0.2%	N/A	0.290%
2/14/2025	MetLife Investment Management LLC	22,678	$1.26M	0.0%	+5.5%	0.059%
2/14/2025	Dimensional Fund Advisors LP	341,305	$18.90M	0.0%	-15.5%	0.893%
2/14/2025	Alpha DNA Investment Management LLC	7,818	$0.43M	0.2%	N/A	0.020%
2/13/2025	Canada Pension Plan Investment Board	82,300	$4.56M	0.0%	+13,616.7%	0.215%
2/13/2025	EAM Investors LLC	71,815	$3.98M	0.6%	N/A	0.188%
2/13/2025	XTX Topco Ltd	11,375	$0.63M	0.1%	N/A	0.030%
2/13/2025	Barclays PLC	74,664	$4.13M	0.0%	-24.3%	0.195%
2/13/2025	Summit Investment Advisors Inc.	3,848	$0.21M	0.2%	+6.8%	0.010%
2/13/2025	Raymond James Financial Inc.	19,999	$1.11M	0.0%	N/A	0.052%
2/13/2025	Advisory Services Network LLC	60,459	$3.35M	0.1%	+59.9%	0.158%
2/13/2025	Capula Management Ltd	6,396	$0.35M	0.0%	N/A	0.017%
2/13/2025	Legal & General Group Plc	26,595	$1.47M	0.0%	-2.1%	0.070%
2/13/2025	Invesco Ltd.	932,115	$51.61M	0.0%	+36.7%	2.438%
2/13/2025	Federated Hermes Inc.	77,714	$4.30M	0.0%	N/A	0.203%
2/13/2025	Atika Capital Management LLC	177,200	$9.81M	1.0%	N/A	0.464%
2/13/2025	Envestnet Asset Management Inc.	12,133	$0.67M	0.0%	-15.8%	0.032%
2/13/2025	Wells Fargo & Company MN	57,004	$3.16M	0.0%	+44.1%	0.149%
2/12/2025	Thoroughbred Financial Services LLC	4,745	$0.26M	0.0%	N/A	0.012%
2/12/2025	Geode Capital Management LLC	838,804	$46.46M	0.0%	+0.4%	2.194%
2/12/2025	Franklin Resources Inc.	9,760	$0.54M	0.0%	-19.8%	0.026%
2/12/2025	Wellington Management Group LLP	136,795	$7.57M	0.0%	-5.9%	0.358%
2/12/2025	AIGH Capital Management LLC	224,713	$12.44M	3.9%	+9.9%	0.588%
2/12/2025	Pictet Asset Management Holding SA	5,130	$0.28M	0.0%	N/A	0.013%
2/12/2025	Blair William & Co. IL	27,230	$1.51M	0.0%	N/A	0.071%
2/12/2025	JPMorgan Chase & Co.	129,184	$7.15M	0.0%	-70.7%	0.338%
2/12/2025	Artisan Partners Limited Partnership	691,299	$38.28M	0.1%	-2.5%	1.808%
2/11/2025	Prudential Financial Inc.	148,735	$8.24M	0.0%	+43.7%	0.389%
2/11/2025	Corebridge Financial Inc.	18,289	$1.01M	0.0%	-7.0%	0.048%
2/11/2025	Crowley Wealth Management Inc.	450	$25K	0.0%	N/A	0.001%
2/11/2025	Vanguard Group Inc.	2,115,162	$117.12M	0.0%	+0.9%	5.533%
2/11/2025	LPL Financial LLC	6,468	$0.36M	0.0%	-44.2%	0.017%
2/11/2025	KLP Kapitalforvaltning AS	5,400	$0.30M	0.0%	N/A	0.014%
2/11/2025	Sei Investments Co.	48,180	$2.67M	0.0%	+35.8%	0.126%
2/11/2025	Teacher Retirement System of Texas	7,904	$0.44M	0.0%	+19.2%	0.021%
2/10/2025	Swiss National Bank	52,333	$2.90M	0.0%	+1.2%	0.137%
2/7/2025	HighTower Advisors LLC	3,734	$0.21M	0.0%	N/A	0.010%
2/7/2025	Essex Investment Management Co. LLC	79,760	$4.42M	0.8%	-26.9%	0.209%
2/7/2025	Lisanti Capital Growth LLC	96,935	$5.37M	1.3%	+143.3%	0.254%
2/6/2025	Raymond James Financial Inc.	19,999	$1.11M	0.0%	N/A	0.052%
2/6/2025	Aigen Investment Management LP	7,504	$0.42M	0.1%	N/A	0.020%
2/6/2025	Victory Capital Management Inc.	4,031	$0.22M	0.0%	N/A	0.011%
2/6/2025	Keybank National Association OH	12,383	$0.69M	0.0%	+24.1%	0.032%
2/6/2025	Charles Schwab Investment Management Inc.	293,700	$16.26M	0.0%	+1.3%	0.768%
2/5/2025	Mutual of America Capital Management LLC	130,097	$7.20M	0.1%	-0.3%	0.340%
2/5/2025	Oppenheimer & Co. Inc.	4,100	$0.23M	0.0%	N/A	0.011%
2/4/2025	Bank of New York Mellon Corp	101,928	$5.64M	0.0%	+0.5%	0.267%

Data available starting January 2016

See Full Table

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Today's Range

Now: $48.09

$45.60

$48.23

50 Day Range

MA: $49.11

$41.29

$56.94

52 Week Range

Now: $48.09

$20.08

$57.28

Volume

487,715 shs

Average Volume

638,840 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Who are the company insiders with the largest holdings of Tarsus Pharmaceuticals?: Tarsus Pharmaceuticals' top insider shareholders include:
Bobak R Azamian (CEO)
Seshadri Neervannan (COO)
Aziz Mottiwala (Insider)
Bryan Wahl (General Counsel)
Leonard M Greenstein (CFO)
Dianne C Whitfield (Insider)
Elizabeth Yeu Lin (Director)
Jose M Trevejo (Insider)
Mark J Holdbrook (VP)
Andrew D Goldberg (Director)
Learn More about top insider investors at Tarsus Pharmaceuticals.
Who are the major institutional investors of Tarsus Pharmaceuticals?: Tarsus Pharmaceuticals' top institutional shareholders include:
RTW Investments LP — 8.47%
Paradigm Biocapital Advisors LP — 6.62%
Jennison Associates LLC — 6.54%
Vanguard Group Inc. — 5.53%
Toronto Dominion Bank — 4.99%
Toronto Dominion Bank — 4.99%
Learn More about top institutional investors of Tarsus Pharmaceuticals stock.
Which institutional investors are selling Tarsus Pharmaceuticals stock?: Within the last quarter, TARS stock was sold by these institutional investors:
TFG Asset Management GP Ltd
TFG Asset Management GP Ltd
JPMorgan Chase & Co.
Two Sigma Investments LP
Two Sigma Advisers LP
Schonfeld Strategic Advisors LLC
RTW Investments LP
Ally Bridge Group NY LLC
In the last year, company insiders that have sold Tarsus Pharmaceuticals company stock include:
Bobak R Azamian (CEO)
Seshadri Neervannan (COO)
Aziz Mottiwala (Insider)
Bryan Wahl (General Counsel)
Learn More investors selling Tarsus Pharmaceuticals stock.
Which institutional investors are buying Tarsus Pharmaceuticals stock?: In the previous quarter, TARS stock was acquired by institutional investors including:
Toronto Dominion Bank
Toronto Dominion Bank
Lord Abbett & CO. LLC
Millennium Management LLC
Gilder Gagnon Howe & Co. LLC
Jennison Associates LLC
Jane Street Group LLC
Invesco Ltd.
Within the last year, these company insiders have bought Tarsus Pharmaceuticals stock:
Bobak R Azamian (CEO)
Seshadri Neervannan (COO)
Learn More investors buying Tarsus Pharmaceuticals stock.